Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pleconaril - Antivirus Therapeutics

Drug Profile

Pleconaril - Antivirus Therapeutics

Alternative Names: Picovir; VP 63843; WIN 63843

Latest Information Update: 11 Mar 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator sanofi-aventis
  • Developer Antivirus Therapeutics; Merck & Co; ViroPharma
  • Class Antidementias; Antivirals; Oxadiazoles; Small molecules
  • Mechanism of Action Virus replication inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Enterovirus infections
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Common cold; Enterovirus infections; Picornavirus infections

Most Recent Events

  • 11 Mar 2019 Discontinued - Phase-II for Enterovirus infections (In neonates, Prevention) in USA, Canada (PO)
  • 03 Dec 2004 Schering-Plough's agreement with ViroPharma to license intranasal pleconaril for treatment of the common cold in the US and Canada became effective upon early termination of the Hart-Scott-Rodino Antitrust Improvement Act
  • 26 Aug 2004 Aventis has merged with Sanofi-Synthelabo to form Sanofi-Aventis
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top